J. Kelly Ganjei

Director at INmune Bio

Mr. Ganjei has been a director since September, 2016]. He is Chief Executive Officer of Cognate BioServices, Inc., a position he has held since 2011. Mr. Ganjei has over 20 years of experience within the life science, venture capital and IT sectors and has lead companies through various stages of development ranging from virtual start-up to mid-cap restart, exponential growth and public exit. Prior to joining Cognate, Mr. Ganjei was Principal at an SBA venture capital firm where he instrumental in supporting deal flow with a specific focus on regenerative medicine, immunotherapy and cell therapy investment opportunities. While in this role, he was the key driver of several other strategic deals for various portfolio companies. Previously, Mr. Ganjei was Chief Executive Officer of Remegenix, Inc., a company he co-founded, and Vice President of Business Development at TissueGene, Inc., where he was instrumental in closing several funding tranches and was responsible for developing the global informatics infrastructure for the company and its affiliates. He also served as Product Marketing Manager for LabVantage, where he was the key technical sales and marketing lead for that firm’s life science software product offering globally and was responsible for the design of all life science product initiatives. He began his career at the National Institutes of Health. Mr. Ganjei has published numerous scientific, peer-reviewed papers and has been a speaker and presenter at various business forums. Mr. Ganjei received his B.S. in Microbiology from the University of Maryland College Park in 1995.

Timeline

  • Director

    Current role